BSBE(SZ:300406) ZHONGTAI SECURITIES·2024-02-25 16:00Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 15% compared to the benchmark index within the next 6 to 12 months [7]. Core Views - The company has acquired Longjin Biotechnology, a leading enterprise in the FISH sector, which is expected to enhance its overall competitiveness [4]. - The acquisition is anticipated to create synergies between the two companies, leveraging existing customer resources and brand advantages to achieve significant revenue growth in the coming years [11]. - The report forecasts continued high growth in the company's pathology and blood coagulation businesses, with traditional biochemical sectors maintaining a leading position [11]. Financial Summary - The company's revenue is projected to grow from 1,511 million yuan in 2022 to 2,099 million yuan in 2024, reflecting a compound annual growth rate (CAGR) of approximately 20% [6]. - Net profit is expected to increase from 389 million yuan in 2022 to 609 million yuan in 2024, with a notable growth rate of 31% in 2023 [11]. - Earnings per share (EPS) is forecasted to rise from 0.66 yuan in 2022 to 1.03 yuan in 2024, indicating a strong upward trend [11]. Investment Highlights - The report emphasizes the strategic importance of the acquisition of Longjin Biotechnology, which is expected to significantly contribute to the company's revenue and overall performance [11]. - The company is positioned to benefit from the high demand in the pathology diagnostics market, with a comprehensive product pipeline and established market presence [11]. - The anticipated revenue growth from Longjin Biotechnology is expected to enhance the company's financial performance and market position [11].